Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 5/20 | 0.72 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.59 |
| ▸ | DPP4 | P27487 | 1/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.55 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.55 |
| ▸ | TNKS | O95271 | 1/20 | 0.54 |
| ▸ | MGAM | O43451 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6083945 | 0.87 | HPGDS (0.76) | HPGDSCXCR4DPP4DPP7TNKS | |
| SCHEMBL6083955 | 0.87 | HPGDS (0.76) | HPGDSCXCR4DPP4DPP7TNKS | |
| SCHEMBL5047611 | 0.84 | HPGDS (0.61) | HPGDSMAOB | |
| SCHEMBL5258735 | 0.82 | HPGDS (0.57) | HPGDSCXCR4TRPV1DPP4DPP7 | |
| SCHEMBL6832879 | 0.82 | HPGDS (0.57) | HPGDSCXCR4TRPV1DPP4DPP7 | |
| SCHEMBL530208 | 0.81 | TRPV1 (0.53) | HPGDSCXCR4TRPV1ACKR3MGAM | |
| SCHEMBL23812943 | 0.80 | HPGDS (1.00) | HPGDS | |
| Hydrochloric Acid SCHEMBL530298 | 0.80 | TRPV1 (0.52) | HPGDSCXCR4TRPV1ACKR3MGAM | |
| SCHEMBL6099360 | 0.79 | HPGDS (0.59) | HPGDSCXCR4DPP4DPP7TNKS | |
| SCHEMBL23812935 | 0.79 | HPGDS (0.64) | HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120749-B2 | Quinoline derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-09-01 | — | — | US | disclosed |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-08-22 | — | — | US | disclosed |
| EP-2597955-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012016082-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NADK, NEK1 | HPGDS 4260/4885CXCR4 3139/4885TRPV1 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.